We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+26.18%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$706M
AUM Growth
+$239M
Cap. Flow
+$173M
Cap. Flow %
24.55%
Top 10 Hldgs %
75.21%
Holding
36
New
6
Increased
3
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
VYNE icon
VYNE Therapeutics
VYNE
+$135M
2
ASND icon
Ascendis Pharma A/S
ASND
+$22.5M
3
QTTB icon
Q32 Bio
QTTB
+$21.7M
4
ARWR icon
Arrowhead Research
ARWR
+$11.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$9.94M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$20.3M
2
AIMT
Aimmune Therapeutics
AIMT
+$11.9M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$4M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.31M
5
KALA icon
KALA BIO
KALA
+$1.75M

Sector Composition

Rank Sector Weight
1 Healthcare 95.38%
2 Materials 2.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYNE icon
1
VYNE Therapeutics
VYNE
$19.1M
$151M 21.35%
+1,114
New +$135M
ASND icon
2
Ascendis Pharma A/S
ASND
$16.7B
$142M 20.07%
2,166,832
+400,000
+23% +$22.5M
BHVN
3
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$52.8M 7.48%
2,049,545
+72,727
+4% +$2.17M
CDXS icon
4
Codexis
CDXS
$136M
$33.6M 4.76%
3,054,825
– –
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$32.2M 4.57%
1,457,834
– –
VRNA
6
DELISTED
Verona Pharma
VRNA
$29.9M 4.23%
1,492,951
– –
ACRS icon
7
Aclaris Therapeutics
ACRS
$744M
$28.9M 4.09%
1,647,214
– –
QTTB icon
8
Q32 Bio
QTTB
$467M
$21.7M 3.07%
+64,430
New +$21.7M
NBRV
9
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$20.5M 2.9%
16,297
– –
AMRS
10
DELISTED
Amyris Inc.
AMRS
$18.9M 2.68%
2,826,711
– –
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$17.6M 2.5%
59,709
– –
SBBP
12
DELISTED
Strongbridge Biopharma plc.
SBBP
$17M 2.4%
1,918,132
-534,265
-22% -$4M
KALA icon
13
KALA BIO
KALA
$12.3M
$16.5M 2.34%
418
-46
-10% -$1.75M
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
$14.2M 2.01%
3,333,333
– –
ARWR icon
15
Arrowhead Research
ARWR
$12.1B
$13.7M 1.94%
+1,900,000
New +$11.7M
RNAC icon
16
Cartesian Therapeutics
RNAC
$225M
$11.4M 1.62%
37,306
– –
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$10.4M 1.47%
+800,000
New +$9.94M
AIMT
18
DELISTED
Aimmune Therapeutics
AIMT
$9.77M 1.38%
306,872
-336,754
-52% -$11.9M
GNCA
19
DELISTED
Genocea Biosciences, Inc.
GNCA
$8.59M 1.22%
+1,022,500
New +$8.49M
SLNO
20
DELISTED
Soleno Therapeutics
SLNO
$7.31M 1.04%
268,902
– –
AUPH icon
21
Aurinia Pharmaceuticals
AUPH
$1.92B
$6.3M 0.89%
1,213,290
– –
ZLAB icon
22
Zai Lab
ZLAB
$2.1B
$6.06M 0.86%
283,787
-33,780
-11% -$766K
SRRA
23
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.05M 0.72%
60,957
– –
RGNX icon
24
Regenxbio
RGNX
$615M
$4.91M 0.7%
164,403
– –
FOMX
25
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.39M 0.62%
855,000
– –
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Vivo Capital held 36 positions worth $706M, up 51% from $467M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Vivo Capital deployed $173M of net new capital in Q1 2018, opening 6 new positions and adding to 3 existing holdings. Its largest new stake was VYNE Therapeutics: 1,114 shares worth $151M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Aimmune Therapeutics, an estimated $11.9M trimmed.

  • Vivo Capital's largest Q1 2018 buy was VYNE Therapeutics: 1,114 shares worth $151M.
  • Vivo Capital added most to Ascendis Pharma A/S in Q1 2018, an estimated $22.5M increase.
  • Vivo Capital's biggest Q1 2018 reduction was Aimmune Therapeutics, cutting an estimated $11.9M.
  • Vivo Capital fully exited Advanced Accelerator Applications S.A. in Q1 2018, selling an estimated $20.3M.
  • Vivo Capital's ten largest holdings make up 75% of its $706M portfolio in Q1 2018.
  • Vivo Capital opened 6 new positions and closed 2 in Q1 2018.
  • Vivo Capital's portfolio value rose 51% quarter-over-quarter to $706M.

Based on Vivo Capital's 13F filing for Q1 2018, filed 15 May 2018.